Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Molecular Biology Research Center, System Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Immunol Lett. 2018 Jul;199:53-60. doi: 10.1016/j.imlet.2018.03.004. Epub 2018 Mar 13.
Brucella (B) species are brucellosis causative agents, a worldwide zoonotic illness causing Malta fever in humans and abortion in domestic animals. In this work, we evaluated the vaccine potential of Trimethyl chitosan (TMC) nanoparticles formulation of Urease (TMC/Urease) against brucellosis. TMC/Urease nanoparticles and urease without any adjuvant were separately administered both orally and intraperitoneally. Intraperitoneal (i.p.) administration of urease alone as well as oral administration of both TMC/Urease nanoparticles and urease alone, elicited low titers of specific immunoglobulin G (IgG), while i.p. immunization with TMC/Urease nanoparticles induced high specific IgG production levels. As it was indicated by the cytokine assay and the antibody isotypes, i.p. immunization by urease alone, and TMC/Urease nanoparticles induced a mixed Th1-Th2 immune response, whereas oral administration of both urease alone and TMC/Urease nanoparticles induced a mixed Th1-Th17 immune response. In lymphocyte proliferation assay, spleen cells from i.p.-vaccinated mice with TMC/Urease nanoparticles showed a strong recall proliferative response. Vaccinated animals were challenged with virulent strains of B. melitensis and B. abortus. I.p. vaccination with TMC/Urease nanoparticles resulted in a high degree of protection. Altogether, our results indicated that TMC nanoparticles are a potent delivery system for i.p.-administered Brucella antigens.
布鲁氏菌(B)种是布鲁氏菌病的病原体,是一种全球性的人畜共患病,可导致人类马尔他热和家畜流产。在这项工作中,我们评估了三甲基壳聚糖(TMC)纳米粒制剂脲酶(TMC/脲酶)对布鲁氏菌病的疫苗潜力。TMC/脲酶纳米粒和无任何佐剂的脲酶分别经口服和腹腔内给药。单独腹腔内(ip)给予脲酶以及单独口服 TMC/脲酶纳米粒和脲酶,均可引起低滴度的特异性免疫球蛋白 G(IgG),而 TMC/脲酶纳米粒的腹腔内免疫可诱导高特异性 IgG 产生水平。如细胞因子分析和抗体同种型所示,单独腹腔内免疫脲酶以及 TMC/脲酶纳米粒诱导了混合的 Th1-Th2 免疫反应,而单独口服脲酶和 TMC/脲酶纳米粒则诱导了混合的 Th1-Th17 免疫反应。在淋巴细胞增殖试验中,TMC/脲酶纳米粒腹腔内免疫的小鼠脾细胞表现出强烈的回忆性增殖反应。接种疫苗的动物受到了强毒力的 B. melitensis 和 B. abortus 菌株的挑战。TMC/脲酶纳米粒的腹腔内免疫可高度保护。总之,我们的结果表明,TMC 纳米粒是一种有效的布鲁氏菌抗原腹腔内给药的递送系统。